Abcam, ab249781, Anti-MEIS2 antibody [EPR12100] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MEIS2 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR12100,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The immunogen of this antibody is, according to BLAST results, highly conserved (93%) with human MEIS1. According to this, the antibody is very likely to cross-react with MEIS1 but this has, to our knowledge, not been experimentally tested so far.

Product details:
ab249781 is the carrier-free version of
ab174270
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MEIS2 or Myeloid Ecotropic Viral Integration Site 2 is a transcription factor known for its role in gene regulation. This protein weighs approximately 52-54 kDa and participates in DNA binding. MEIS2 is highly expressed in tissues like the brain heart and kidneys especially during developmental stages. MEIS2 functions through direct interaction with genomic regions to regulate the transcription of target genes.
Biological function summary
MEIS2 influences cell differentiation and organ development. It interacts with other proteins as part of a complex including the HOX and PBX families to fine-tune transcriptional outcomes. MEIS2 plays a role in neuronal development where its activity helps shape the neural tissue architecture. Researchers observe that MEIS2 affects cellular processes important for forming correctly structured organs.
Pathways
MEIS2 is engaged in the retinoic acid signaling pathway and the Notch signaling pathway. These pathways are vital in embryonic development and cellular differentiation. MEIS2's interaction with the PBX1 protein demonstrates its importance in pathways that lead to precise gene expression during development. Together they contribute to regulating the transcriptional networks involved in developmental processes.
MEIS2 has links to certain developmental disorders and cancers. Mutations or aberrant expression of MEIS2 correlate with conditions like cleft palate and neuroblastoma. Notably its interaction with the HOXA9 protein has been documented in certain types of leukemia showing how MEIS2-related pathways can contribute to abnormal cell proliferation. Understanding these interactions aids research into potential targets for therapeutic intervention.